Pulse Biosciences, Inc. PLSE
We take great care to ensure that the data presented and summarized in this overview for Pulse Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PLSE
View all-
Black Rock Inc. New York, NY1.15MShares$24.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA996KShares$20.9 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC786KShares$16.5 Million0.0% of portfolio
-
State Street Corp Boston, MA461KShares$9.69 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA457KShares$9.6 Million0.0% of portfolio
-
Griffin Asset Management, Inc.257KShares$5.41 Million0.51% of portfolio
-
Northern Trust Corp Chicago, IL210KShares$4.41 Million0.0% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA148KShares$3.11 Million0.0% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL115KShares$2.42 Million0.0% of portfolio
-
Morgan Stanley New York, NY70.2KShares$1.47 Million0.0% of portfolio
Latest Institutional Activity in PLSE
Top Purchases
Top Sells
About PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Insider Transactions at PLSE
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 13
2024
|
Robert W Duggan Director |
BUY
Open market or private purchase
|
Direct |
55,256
+0.13%
|
$939,352
$17.18 P/Share
|
Dec 12
2024
|
Robert W Duggan Director |
BUY
Open market or private purchase
|
Direct |
45,404
+0.11%
|
$771,868
$17.13 P/Share
|
Dec 11
2024
|
Robert W Duggan Director |
BUY
Open market or private purchase
|
Direct |
56,054
+0.07%
|
$952,918
$17.08 P/Share
|
Sep 24
2024
|
Mitchell E. Levinson Chief Strategy Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
2,206
+4.14%
|
$24,266
$11.0 P/Share
|
Sep 24
2024
|
Mitchell E. Levinson Chief Strategy Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
3,000
+3.1%
|
$33,000
$11.0 P/Share
|
Jul 19
2024
|
Burke Thomas Barrett President and CEO |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
1,086
+4.37%
|
$11,946
$11.0 P/Share
|
Jul 03
2024
|
Maky Zanganeh Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
60,242
+8.3%
|
-
|
Jul 03
2024
|
Robert W Duggan Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
118,332
+10.95%
|
-
|
Jul 03
2024
|
Robert W Duggan Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
5,187,824
+10.95%
|
-
|
Jul 03
2024
|
Kevin Patrick Danahy Chief Commercial Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
650
+1.75%
|
-
|
Jul 03
2024
|
Mitchell E. Levinson Chief Strategy Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
2,207
+4.33%
|
-
|
Jul 03
2024
|
Mitchell E. Levinson Chief Strategy Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
3,000
+3.2%
|
-
|
Jul 03
2024
|
Burke Thomas Barrett President and CEO |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
1,086
+8.92%
|
-
|
May 20
2024
|
Burke Thomas Barrett President and CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$80,000
$8.56 P/Share
|
Dec 12
2023
|
Robert W Duggan Director |
BUY
Open market or private purchase
|
Direct |
17,999
+0.05%
|
$161,991
$9.15 P/Share
|
Dec 11
2023
|
Robert W Duggan Director |
BUY
Open market or private purchase
|
Direct |
90,118
+0.24%
|
$811,062
$9.36 P/Share
|
Dec 08
2023
|
Robert W Duggan Director |
BUY
Open market or private purchase
|
Direct |
116,656
+0.32%
|
$1,049,904
$9.54 P/Share
|
Dec 07
2023
|
Robert W Duggan Director |
BUY
Open market or private purchase
|
Direct |
74,852
+0.2%
|
$673,668
$9.19 P/Share
|
Dec 06
2023
|
Robert W Duggan Director |
BUY
Open market or private purchase
|
Direct |
82,813
+0.23%
|
$745,317
$9.06 P/Share
|
Dec 06
2023
|
Robert W Duggan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,933
+0.03%
|
$49,665
$5.95 P/Share
|
Last 12 Months Summary
Open market or private purchase | 167K shares |
---|---|
Exercise of in-the-money or at-the-money derivatives securities | 5.38M shares |